TheEdgeResearch
Home / Stocks / LVTX

LAVA Therapeutics N.V. (LVTX)

NASDAQ Healthcare Biotechnology
$1.74 ▼ -3.87%
Market Cap
$45.8M
Sector
Healthcare
Industry
Biotechnology
Beta
0.50
52-Wk Range
0.85-2
CEO
Stephen Allen Hurly
Country
NL
Currency
USD

LAVA Therapeutics N.V. operates in the Biotechnology industry of the Healthcare sector, headquartered in Utrecht, NL. The stock last traded at $1.74, down 3.87% on the session, giving a market capitalisation of $45.8M. On trailing twelve-month figures it carries a trailing P/E of -2.95, a net margin of 0.0%. Its beta of 0.50 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-2.95
Price / Sales
0.00
Price / Book
3.69
EV / EBITDA
0.25
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.00
Current ratio
12.27
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
34
IPO date
2021-03-26
Headquarters
Utrecht, NL
About LAVA Therapeutics N.V.

LAVA Therapeutics N.V. is an immuno-oncology firm, currently in the clinical development phase, dedicated to pioneering novel therapies for cancer. Utilizing its proprietary Gammabody platform, the company engineers innovative bispecific antibodies. These antibodies are specifically designed to engage and harness the potent and precise capabilities of gamma delta T cells, aiming to stimulate a robust anti-tumor immune response and ultimately enhance outcomes for individuals battling cancer. Key compounds in its clinical pipeline include LAVA-051, currently undergoing Phase 1/2a trials for various hematologic malignancies such as chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. Another front-runner, LAVA-1207, is also in Phase 1/2a clinical studies, targeting metastatic castration-resistant prostate cancer. Furthermore, LAVA Therapeutics is advancing additional Gammabody candidates: LAVA-1223, an investigational treatment for specific solid tumors that targets the epidermal growth factor receptor (EGFR), and preclinical assets LAVA-1266 and LAVA-1278, intended for a range of blood cancers. The company has also forged a research collaboration and licensing partnership with Janssen Biotech, Inc. This alliance focuses on the potential discovery and development of multi-specific antibody therapies aimed at a particular target across diverse therapeutic applications. Established in 2016, LAVA Therapeutics N.V. operates from its headquarters in Utrecht, the Netherlands.

Comparable companies

LAVA Therapeutics N.V. is most often compared with the following Healthcare names:

ATNMCALCCELUELUTLTRNPDSBRVPHTPSTTVRDXLO
More research on LVTX
LVTX technical analysis LVTX TheEdge Score Compare against peers
Open full interactive analysis & DCF →